Common Contracts
10 similar null contracts by Athersys, Inc / New, Genetic Technologies LTD, Biohitech Global, Inc., others
BioHiTech GlobalBiohitech Global, Inc. • September 6th, 2019 • Services-educational services • New York
Lishan Aklog, M.D. Chairman & Chief Executive Officer PAVmed Inc. One Grand Central Place, Suite 4600 New York, NY 10165 Dear Dr. Aklog:PAVmed Inc. • April 12th, 2019 • Surgical & medical instruments & apparatus • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and PAVmed Inc. (the “Company”), that Maxim shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered shares (the “Shares” or the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement shall be collectively referred to herein as the “Transacti
Mr. Marc Voigt Chief Executive Officer Prima BioMed Ltd Level 12, 95 Pitt Street, Sydney, 2000 New South Wales, Australia Dear Marc:Prima BioMed LTD • June 29th, 2017 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Prima BioMed Ltd (the “Company”), that Maxim shall serve as the lead placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered American Depositary Shares (the “ADSs”), each evidencing one hundred Ordinary Shares of the Company (the “Ordinary Shares”) and Warrants to purchase ADSs. The terms of the Placement and the ADSs and warrants shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any ADSs or Warrants or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement shall be col
Mr. Eutillio Buccilli Chief Executive Officer Genetic Technologies LimitedGenetic Technologies LTD • December 2nd, 2016 • Biological products, (no disgnostic substances) • New York
Mr. W. John Short Chief Executive Officer RiceBran TechnologiesRiceBran Technologies • February 17th, 2016 • Grain mill products • New York
Mr. Zami Aberman, Chairman of Board of Directors & Chief Executive OfficerPluristem Therapeutics Inc • June 25th, 2015 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Pluristem Therapeutics Inc. (the “Company”), that Maxim shall serve as the lead placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) registered shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants (the “Warrants”) to purchase shares of Common Stock (the shares of Common Stock underlying the Warrants, “Warrant Shares” and, together with the Shares and the Warrants, the “Securities”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or com
Mr. Eutillio Buccilli Chief Executive Officer Genetic Technologies LimitedGenetic Technologies LTD • March 6th, 2015 • Biological products, (no disgnostic substances) • New York
Mr. Dwight Babcock Chairman & Chief Executive Officer IsoRay, Inc.IsoRay, Inc. • March 21st, 2014 • Surgical & medical instruments & apparatus • New York
Mr. Gil Van Bokkelen Chief Executive Officer Athersys, Inc.Athersys, Inc / New • January 13th, 2014 • Pharmaceutical preparations • New York
Mr. Gil Van Bokkelen Chief Executive Officer Athersys, Inc.Athersys, Inc / New • November 29th, 2013 • Pharmaceutical preparations • New York
